Ra­tio rais­es $50M as ra­dio­phar­ma field finds its groove

Ra­dio­phar­ma­ceu­ti­cal biotech Ra­tio Ther­a­peu­tics has raised a $50 mil­lion Se­ries B to bring its first ther­a­peu­tic in­to the clin­ic, it said Wednes­day morn­ing.

The biotech has now raised a to­tal of $90 mil­lion since its found­ing in mid-2021. Based in Boston’s Sea­port Dis­trict, the biotech un­veiled it­self in June 2022 and has al­ready inked col­lab­o­ra­tions with Bay­er, Mer­ck and Lan­theus.

Ra­dio­phar­ma com­pa­nies have been in the news with con­sid­er­ably more fre­quen­cy in re­cent months with two key ac­qui­si­tions by Eli Lil­ly and Bris­tol My­ers Squibb, and fi­nanc­ing rounds rolling in for a string of star­tups, like Art­bio, Con­ver­gent Ther­a­peu­tics and Ab­dera Ther­a­peu­tics. Bris­tol My­ers in­vest­ed in Ra­tio’s Se­ries B. The ex­pand­ing mar­ket is al­so caus­ing CD­MOs to iron out sup­ply chain bumps and con­fig­ure ac­cess to raw ma­te­ri­als.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER